Cargando…
P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429433/ http://dx.doi.org/10.1097/01.HS9.0000969392.14818.fb |
| _version_ | 1785090711968808960 |
|---|---|
| author | Yosifov, Deyan von Tresckow, Julia Giza, Adam Robrecht, Sandra Schneider, Christof Jebaraj, Billy Mertens, Daniel Ritgen, Matthias Schilhabel, Anke Kreuzer, Karl-Anton Maria Fink, Anna Al-Sawaf, Othman Langerbeins, Petra Fischer, Kirsten Eichhorst, Barbara Hallek, Michael Döhner, Hartmut Stilgenbauer, Stephan Cramer, Paula Tausch, Eugen |
| author_facet | Yosifov, Deyan von Tresckow, Julia Giza, Adam Robrecht, Sandra Schneider, Christof Jebaraj, Billy Mertens, Daniel Ritgen, Matthias Schilhabel, Anke Kreuzer, Karl-Anton Maria Fink, Anna Al-Sawaf, Othman Langerbeins, Petra Fischer, Kirsten Eichhorst, Barbara Hallek, Michael Döhner, Hartmut Stilgenbauer, Stephan Cramer, Paula Tausch, Eugen |
| author_sort | Yosifov, Deyan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429433 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104294332023-08-17 P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS Yosifov, Deyan von Tresckow, Julia Giza, Adam Robrecht, Sandra Schneider, Christof Jebaraj, Billy Mertens, Daniel Ritgen, Matthias Schilhabel, Anke Kreuzer, Karl-Anton Maria Fink, Anna Al-Sawaf, Othman Langerbeins, Petra Fischer, Kirsten Eichhorst, Barbara Hallek, Michael Döhner, Hartmut Stilgenbauer, Stephan Cramer, Paula Tausch, Eugen Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429433/ http://dx.doi.org/10.1097/01.HS9.0000969392.14818.fb Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Yosifov, Deyan von Tresckow, Julia Giza, Adam Robrecht, Sandra Schneider, Christof Jebaraj, Billy Mertens, Daniel Ritgen, Matthias Schilhabel, Anke Kreuzer, Karl-Anton Maria Fink, Anna Al-Sawaf, Othman Langerbeins, Petra Fischer, Kirsten Eichhorst, Barbara Hallek, Michael Döhner, Hartmut Stilgenbauer, Stephan Cramer, Paula Tausch, Eugen P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS |
| title | P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS |
| title_full | P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS |
| title_fullStr | P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS |
| title_full_unstemmed | P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS |
| title_short | P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS |
| title_sort | p622: genetic markers and outcome of cll patients in combined time-limited treatment with anti-cd20 antibody + ibrutinib, idelalisib or venetoclax in the gcllsg cll2-bag, -bcg, -big and -bio phase-ii trials |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429433/ http://dx.doi.org/10.1097/01.HS9.0000969392.14818.fb |
| work_keys_str_mv | AT yosifovdeyan p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT vontresckowjulia p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT gizaadam p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT robrechtsandra p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT schneiderchristof p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT jebarajbilly p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT mertensdaniel p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT ritgenmatthias p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT schilhabelanke p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT kreuzerkarlanton p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT mariafinkanna p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT alsawafothman p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT langerbeinspetra p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT fischerkirsten p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT eichhorstbarbara p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT hallekmichael p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT dohnerhartmut p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT stilgenbauerstephan p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT cramerpaula p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials AT tauscheugen p622geneticmarkersandoutcomeofcllpatientsincombinedtimelimitedtreatmentwithanticd20antibodyibrutinibidelalisiborvenetoclaxinthegcllsgcll2bagbcgbigandbiophaseiitrials |